Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

45P - DCVAC/LuCa with chemotherapy in patients with stage IV, non-squamous NSCLC without EGFR/ALK aberrations: Five-year survival update


31 Mar 2023


Poster Display session


Xuxinyi Ling


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


X. Ling1, R. Zhong2, S. cao3, L. Zhang3, J. Xu3, B. Zhang2, X. Zhang2, H. Wang3, B. Han4, H. Zhong5

Author affiliations

  • 1 Shanghai/CN
  • 2 Shanghai Chest Hospital, Shanghai Jiao Tong University, 200030 - Shanghai/CN
  • 3 Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN
  • 4 Shanghai Chest Hospital, Shanghai/CN
  • 5 Shanghai Chest Hospital , School of Medicine,Shanghai Jiao Tong University, 200030 - Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 45P


Our study was the first clinical trial showing the safety and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with chemo in Chinese NSCLC patients (Zhong R, Ling X, et al. ESMO Open 2022). The OS data was not mature in our last report. Here, we present a survival update based on 33 months of additional follow-up.


Patients with stage IV, non-squamous NSCLC, no known EGFR/ALK aberrations, and who had not received systemic therapy for NSCLC prior to treatment, were enrolled in this study. Patients were treated with carboplatin/pemetrexed for up to 6 cycles, followed by pemetrexed maintenance for up to 21 cycles. Non-progression patients after two cycles of chemotherapy, assessed as mITT population, received DCVAC/LuCa subcutaneously (s.c.) on day 15 of cycle 3, and thereafter q3w (day 15 of chemotherapy cycles) for up to 15 doses. The dose of DCVAC/LuCa s.c. depended on the baseline number of leucocytes of each patient.


A total of 61 patients were enrolled. At the clinical cutoff date (14 Dec 2022), the median follow-up was 64 months. In the mITT population (n = 44), the median OS was 27.4 months (95% CI, 18.1 to 36.7 months), the 3-year OS rate was 37.2% and the 5-year OS rate was 23.4%. Among the 15 patients who completed 15 cycles of DC vaccination, 6 (40%) remained alive at a 5-year follow-up. Patients who received higher-dose DCVAC/LuCa had a better prognosis than patients who received lower-dose DCVAC/LuCa.


The combination of DCVAC/LuCa and chemo continued to provide long-term benefits as a first-line treatment in Chinese patients with stage IV, non-squamous NSCLC without EGFR/ALK aberrations. The long-term benefits and the good safety profile support the conduct of a validation trial in a larger population with greater diversity.

Legal entity responsible for the study

SOTIO Medical Research (Beijing) Co., Ltd.


SOTIO Medical Research (Beijing) Co., Ltd.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.